LYRA THERAPEUTICS INC (LYRA) Stock Income Statement
NASDAQ:LYRA - Nasdaq - US55234L1052 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.53M | 1.56M | 1.36M | 290.00K | 0.00 | |||
| Operating Expenses | 62.27M | 67.09M | 56.35M | 43.90M | 22.21M | |||
| Research and Development | 43.77M | 48.03M | 38.80M | 29.69M | 12.52M | |||
| Selling, General, and Administrative Expenses | 18.50M | 19.06M | 17.56M | 14.21M | 9.69M | |||
| Operating Income | -60.73M | -65.53M | -54.99M | -43.62M | -22.21M | |||
| Interest Income/Expense | 2.95M | 4.50M | 1.04M | 100.00K | 80.00K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | -35.62M | -1.59M | -1.32M | N/A | N/A | |||
| Income Before Taxes | -93.40M | -62.62M | -55.27M | -43.51M | -22.13M | |||
| Income Tax | 39.00K | 59.00K | 10.00K | N/A | N/A | |||
| Net Income | -93.44M | -62.68M | -55.28M | -43.51M | -22.24M | |||
| EBITDA | -60.26M | -65.25M | -53.92M | -42.62M | -22.11M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.44 | -1.26 | -1.83 | -3.35 | -2.59 | |||
| Non GAAP EPS | -1.43 | -1.25 | -1.75 | -3.35 | -20.21 | |||
| Statistics | ||||||||
| Profit Margin | -6090.94% | -4023.11% | -4064.71% | -15003.45% | N/A | |||
| Operating Profit Margin | -3959.13% | -4205.91% | -4043.38% | -15041.38% | N/A | |||
All data in USD